Fibrex Medical successfully completed first dosing with its lead product, the anti-inflammatory peptide FX06. FX06 is developed to prevent reperfusion injury, an undesired inflammatory reaction after acute myocardial infarction. The now-completed clinical trial measured tolerability and pharmacokinetics of FX06 in healthy volunteers. The study confirmed the excellent safety profile that has already been seen in experimental animal studies.
The clinical trial was performed at Medical University of Vienna in Austria. In total, 30 healthy participants received different doses of FX06 or a placebo, respectively. The results confirmed that even in high doses FX06 was very well-tolerated with no adverse effects observed.